| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Internal Medicine [J-T. L., M-S. W., J-C. S., T-H. W. ], Pathology [C-T. S.], and Surgery [W-J. L.], College of Medicine, National Taiwan University, Taipei, Taiwan
To investigate the molecular mechanism of gastric carcinogenesis, we examined simultaneously the frequency of microsatellite instability and the immunoreactivities to ras, erbB-2, and p53 in 42 gastric adenocarcinoma tissues. Microsatellite instability, measured by DNA replication error, was detected in 33.3% (14/42) of patients with gastric carcinoma while positive immunostaining was demonstrated in 3.1% (1/32) for ras, 40.5% (17/42) for erbB-2, and 28.6% (12/42) for p53. There was no statistical difference between the intestinal type and the diffuse type of carcinoma with respect to microsatellite instability, ras, or erbB-2 expression. The expression of p53 occurred more frequently in the intestinal type of carcinoma (41.7%, 10/24) than in the diffuse type of carcinoma (11.1%, 2/18; P < 0.01). There was no association between microsatellite instability and ras or p53 expression, while enhanced expression of erbB-2 occurred more frequently in carcinomas with microsatellite instability (64.3%, 9/14) than in those without microsatellite instability (28.6%, 8/28; P < 0.05). Such a strong association between microsatellite instability and erbB-2 oncogene may be responsible for the increase of other oncogenic mutations and tumor progression in gastric carcinogenesis.
1 This study was supported by Grant DOH-84-TD-010 from the National Science Council and the Department of Health, Executive Yuan, Taiwan, Republic of China.
2 To whom requests for reprints should be addressed, at Department of Internal Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, Taiwan.
Received 12/12/94. Accepted 2/14/95.
This article has been cited by other articles:
![]() |
C. Gravalos and A. Jimeno HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target Ann. Onc., September 1, 2008; 19(9): 1523 - 1529. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yamashita, H. L. Park, M. S. Kim, M. Osada, Y. Tokumaru, H. Inoue, M. Mori, and D. Sidransky PGP9.5 Methylation in Diffuse-Type Gastric Cancer. Cancer Res., April 1, 2006; 66(7): 3921 - 3927. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tanner, M. Hollmen, T. T. Junttila, A. I. Kapanen, S. Tommola, Y. Soini, H. Helin, J. Salo, H. Joensuu, E. Sihvo, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II{alpha} gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann. Onc., February 1, 2005; 16(2): 273 - 278. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. H. Kim, N.-G. Kim, J. G. Lim, C. Park, and H. Kim Chromosomal Alterations in Paired Gastric Adenomas and Carcinomas Am. J. Pathol., February 1, 2001; 158(2): 655 - 662. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Oliveira, R. Seruca, M. Seixas, and M. Sobrinho-Simoes The Clinicopathological Features of Gastric Carcinomas with Microsatellite Instability May Be Mediated by Mutations of Different ""Target Genes"" : A Study of the TGFß RII, IGFII R, and BAX Genes Am. J. Pathol., October 1, 1998; 153(4): 1211 - 1219. [Abstract] [Full Text] [PDF] |
||||
![]() |
J D HAYDEN, I G MARTIN, L CAWKWELL, and P QUIRKE The role of microsatellite instability in gastric carcinoma Gut, February 1, 1998; 42(2): 300 - 303. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |